Actively Recruiting
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Led by Cartesian Therapeutics · Updated on 2026-04-08
50
Participants Needed
2
Research Sites
150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
CONDITIONS
Official Title
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least age 12
- Definitive diagnosis of childhood-onset systemic lupus erythematous, juvenile myasthenia gravis, juvenile dermatomyositis, or ANCA-associated vasculitis
- Signs and symptoms of moderate disease
- History of systemic treatment
- Parent, guardian, or patient must be able to give written informed consent
You will not qualify if you...
- Major chronic illness not well managed at study entry that may increase risk
- Abnormal blood clotting tests or on anticoagulation therapy except in specified stable conditions
- Absolute neutrophil count less than 1000 cells/microliter
- Hemoglobin less than 8.0 g/dL
- Platelet count less than 50,000/mm3 (platelet transfusions allowed)
- Liver enzymes (ALT, AST, GGT) three times or more above normal
- Creatinine clearance less than 30 mL/min/1.73 m2
- History of primary immunodeficiency or bone marrow transplant
- Positive for hepatitis B surface antigen
- Positive hepatitis C antibody with detectable virus
- Positive HIV test or history
- Active tuberculosis or positive QuantiFERON test
- Any other lab abnormality that may affect participation
- Significant active heart or lung disease unrelated to primary condition, except controlled asthma or COPD
- Arterial or venous blood clots in past 3 months
- History of cancer treated within past 3 years except certain skin or surgically removed cancers without chemotherapy or radiation
- Treatment with investigational drugs within 4 weeks or 5 half-lives prior to screening
- Live vaccination within 4 weeks prior to baseline or planned during study (mRNA vaccines excluded)
- Significant recurrent or active infections interfering with participation
- Psychiatric illness interfering with participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
H01- Children's National Hospital
Washington D.C., District of Columbia, United States, 20010
Actively Recruiting
2
H03- Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
C
Cartesian Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here